Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL

“Our analysis showed that yes, with appropriate safety guards and training and infrastructure, CAR T cell therapy, especially axi-cel, which has highest risk of cytokine release syndrome and neurotoxicity compared to other CD19-directed CAR T cell therapies such as tisa-cel and liso-cel, it can be still safely given.”

Clinicians from University of Vanderbilt investigated outcomes with remote monitoring patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel; Yescarta) and found that safety and efficacy outcomes were similar between patients treated in inpatient and outpatient settings. Data from the retrospective analysis were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke with coauthor Bhagirathbhai Dholaria, MBBS, assistant professor of medicine at Vanderbilt University Medical Center, to learn more about the study and the favorable outcomes observed in patients treated in the outpatient setting. He discussed the advantages for both patients and hospitals with outpatient chimeric antigen receptor (CAR) T-cell therapy treatments.

For more coverage of the 2023 Tandem Meetings, click here.

REFERENCE

Akosile TA, Dholaria B, Baer B, et al. The impact of telemedicine and wearable devices in improving the safety profile of outpatient chimeric antigen receptor T-Cell (CAR-T) therapies: A case-control study. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Abstract #201